Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 19/20 | 1.00 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.68 |
| ▸ | JAK3 | P52333 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17498542 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16219918 | 1.00 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17498569 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16219775 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16219948 | 0.91 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL17498491 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16219853 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL16219905 | 0.87 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL16219892 | 0.87 | EGFR (1.00) | EGFRERBB2 | |
| SCHEMBL17498502 | 0.87 | EGFR (1.00) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-9556191-B2 | Aminoquinazoline derivatives and their salts and methods of use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-01-31 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-02-11 | — | — | US | disclosed |
| WO-2014177038-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039838-A1 | AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE THEREOF | WNK1, ABL1, NEK4 | EGFR 1223/4885ERBB2 368/4885ERBB4 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.